Therapy Detail

Therapy Name GDC-0917
Therapy Description

GDC-0917 is a SMAC mimetic, which acts as an antagonist to Inhibitor of Apoptosis Protein (IAP) family proteins, resulting in decreased tumor growth (PMID: 24041744).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
GDC-0917 CUDC-427 SMAC Mimetic 8 GDC-0917 is a SMAC mimetic, which acts as an antagonist to Inhibitor of Apoptosis Protein (IAP) family proteins, resulting in decreased tumor growth (PMID: 24041744).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable GDC-0917 Phase I Actionable In a Phase I clinical trial, GDC-0917 demonstrated safety and preliminary efficacy in patients with advanced solid tumors (J Clin Oncol 31, 2013 (suppl; abstr 2503)). detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01908413 Phase I GDC-0917 Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma Terminated